Valproic acid and plasma levels of phenytoin. 1979

J Bruni, and B J Wilder, and L J Willmore, and B Barbour

Eight patients were treated concurrently with a constant dose of phenytoin and valproic acid for 1 year. During initial therapy with valproic acid, total plasma phenytoin levels decreased. The interaction was transient and was not observed at the end of 1 year. Total plasma phenytoin levels returned to pre-valproic-acid levels in seven patients.

UI MeSH Term Description Entries
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid

Related Publications

J Bruni, and B J Wilder, and L J Willmore, and B Barbour
April 1983, Revista clinica espanola,
J Bruni, and B J Wilder, and L J Willmore, and B Barbour
January 1979, Therapeutic drug monitoring,
J Bruni, and B J Wilder, and L J Willmore, and B Barbour
December 1978, British journal of clinical pharmacology,
J Bruni, and B J Wilder, and L J Willmore, and B Barbour
January 1979, Therapeutic drug monitoring,
J Bruni, and B J Wilder, and L J Willmore, and B Barbour
January 1983, The Western journal of medicine,
J Bruni, and B J Wilder, and L J Willmore, and B Barbour
December 1979, British journal of clinical pharmacology,
J Bruni, and B J Wilder, and L J Willmore, and B Barbour
January 1981, Therapeutic drug monitoring,
J Bruni, and B J Wilder, and L J Willmore, and B Barbour
December 1980, Clinical pharmacology and therapeutics,
J Bruni, and B J Wilder, and L J Willmore, and B Barbour
October 1982, Drug intelligence & clinical pharmacy,
J Bruni, and B J Wilder, and L J Willmore, and B Barbour
August 1995, Therapeutic drug monitoring,
Copied contents to your clipboard!